For the year ended December 31, 2023, Hualien Pharmaceuticals recorded revenue of RMB76.6 million, an increase over the same period last year. However, the company's year-over-year loss widened to RMB211.2 million due to increased R&D expenses and sales costs. The Group continues to focus on the development and commercialization of dorzagliatin and in August 2020 signed an exclusive promotion service agreement with a third party, receiving an upfront payment of RMB300 million. In addition, the company received a milestone payment of RMB 400 million once the NDA was approved in October 2022. The company's management remains optimistic about future developments and focuses on dorzagliatin's potential as a foundational therapy for type 2 diabetes.

For the year ended December 31, 2023, Hualien Pharmaceuticals recorded revenue of RMB76.6 million, an increase over the same period last year. However, the company's year-over-year loss widened to RMB211.2 million due to increased R&D expenses and sales costs. The Group continues to focus on the development and commercialization of dorzagliatin and in August 2020 signed an exclusive promotion service agreement with a third party, receiving an upfront payment of RMB300 million. In addition, the company received a milestone payment of RMB 400 million once the NDA was approved in October 2022. The company's management remains optimistic about future developments and focuses on dorzagliatin's potential as a foundational therapy for type 2 diabetes.